

Quality-Data Code Submission Error Report

3rd Quarter 2011 Physician Quality Reporting System

Report Date: 02/13/2012

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

QDC Submission Attempts:

- Total QDCs Reported - The number of instances where a TIN/NPI submitted a QDC for that measure.
- Total Valid QDCs Reported on Eligible Cases - The number of instances where a TIN/NPI submitted a valid QDC for that measure.
- % Valid – Percentage of Total Valid QDCs Reported divided by Total QDCs Reported on Eligible Cases.
- Total QDCs Reported on Eligible Cases – Number of valid or invalid QDCs reported on eligible cases meeting the measure's denominator requirements.

Denominator Mismatch:

- Measure Reported with Incorrect Age and/or Gender - The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.
- Incorrect Diagnosis and/or HCPCS - The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
- Measure Reported on an Instance with a Missing CPT Code - The number of occurrences of QDC reporting when there are no CPT codes for billable services on the claim associated with the denominator requirements for the measure.

How to Read the Quality-Data Code Submission Error Report by Measure:

Using Measure #1-Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus as an example, we find the following information as we read across each column:

481,601 QDC submissions were received for this measure, 383,749 of which were considered valid. Therefore, the Valid Submission Rate is 79.68%. There were a total of 384,210 QDCs reported on eligible cases. The rest of the columns explain reasons for invalid submissions for measure #1. We see that 79,783 (16.57%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 92,023 (19.11%) submissions were for patient encounters and/or diagnoses that are not listed in the denominator; 1,533 (0.32%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, TIN/NPI.

Analysis Findings Include:

Quality-Data Code Submission Error Report by Individual Measure (Claims)

1. The top 5 measures with the highest percentage of valid QDC codes submitted were:
 - #203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control (98.88%),
 - #202 Ischemic Vascular Disease (IVD): Complete Lipid Profile (98.40%),
 - #204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic (98.37%),

#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (98.33%) , and
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy (97.86%).

2. The top 5 measures with the lowest percentage of valid QDC codes submitted (with at least 1 eligible instance) were:
 - #188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (0.05%),
 - #66 Appropriate Testing for Children with Pharyngitis (0.22%),
 - #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (0.34%),
 - #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (0.46%), and
 - #94 Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility (0.60%).

3. The 5 measures with the highest rate of HCPCS/diagnosis errors were:
 - #188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (98.06%),
 - #189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days (94.82%),
 - #66 Appropriate Testing for Children with Pharyngitis (94.77%),
 - #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (94.40%), and
 - #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (93.84%).

4. The 5 measures with the highest rate of patient age/gender errors were:
 - #66 Appropriate Testing for Children with Pharyngitis (99.67%),
 - #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (99.66%),
 - #94 Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility (98.80%),
 - #231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (94.44%), and
 - #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (87.28%).

Physician Quality Reporting - Quality Data Code Submission Error Report by Individual Measure (Claims)

Report Includes Claims Data for Services Provided from January 1, 2011 through September 30, 2011 and Processed by September 30, 2011

Clinical Condition and Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	481,601	383,749	79.68%	384,210	79,783	16.57%	92,023	19.11%	1,533	0.32%
#2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	439,826	350,723	79.74%	351,325	69,517	15.81%	83,975	19.09%	1,383	0.31%
#3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	519,293	361,372	69.59%	372,416	97,744	18.82%	140,593	27.07%	1,709	0.33%
#6 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	705,309	651,220	92.33%	651,220	0	0.00%	52,107	7.39%	1,686	0.24%
#9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	16,861	12,747	75.60%	12,747	0	0.00%	3,798	22.53%	273	1.62%
#10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	380,019	324,612	85.42%	343,999	0	0.00%	33,587	8.84%	1,512	0.40%
#12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	912,810	750,989	82.27%	751,465	0	0.00%	159,720	17.50%	1,122	0.12%
#14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	924,848	889,475	96.18%	889,796	1,079	0.12%	33,496	3.62%	1,392	0.15%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	303,003	250,652	82.72%	250,706	0	0.00%	51,594	17.03%	525	0.17%
#19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	221,805	130,206	58.70%	162,222	0	0.00%	59,062	26.63%	331	0.15%
#20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	118,377	89,938	75.98%	89,938	11	0.01%	27,472	23.21%	967	0.82%
#21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	176,970	137,953	77.95%	137,954	16	0.01%	37,756	21.33%	1,260	0.71%
#22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	168,823	93,930	55.64%	119,067	15	0.01%	48,248	28.58%	1,508	0.89%
#23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	147,218	113,518	77.11%	113,518	19	0.01%	32,728	22.23%	972	0.66%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Clinical Condition and Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	7,946	3,251	40.91%	3,251	51	0.64%	4,110	51.72%	49	0.62%
#28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	52,978	50,058	94.49%	50,060	0	0.00%	2,687	5.07%	109	0.21%
#30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	2,992,655	2,406,029	80.40%	2,416,022	207	0.01%	562,804	18.81%	13,829	0.46%
#31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	15,828	12,844	81.15%	12,844	0	0.00%	2,866	18.11%	96	0.61%
#32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	20,700	17,735	85.68%	17,735	0	0.00%	2,788	13.47%	140	0.68%
#35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	10,811	7,175	66.37%	8,239	0	0.00%	2,529	23.39%	32	0.30%
#36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	15,459	12,968	83.89%	13,001	0	0.00%	2,331	15.08%	96	0.62%
#39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	372,581	342,661	91.97%	342,661	18,131	4.87%	26,849	7.21%	3,071	0.82%
#40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	22,076	1,312	5.94%	1,312	278	1.26%	20,185	91.43%	41	0.19%
#41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	55,771	44,327	79.48%	44,327	444	0.80%	10,949	19.63%	327	0.59%
#43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	20,412	13,847	67.84%	13,849	0	0.00%	6,373	31.22%	190	0.93%
#44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	14,142	9,441	66.76%	9,441	0	0.00%	4,534	32.06%	167	1.18%
#45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	153,844	34,158	22.20%	42,254	10	0.01%	109,637	71.27%	1,953	1.27%
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	25,480	4,481	17.59%	9,646	884	3.47%	2,402	9.43%	749	2.94%
#47 Advance Care Plan	818,884	720,261	87.96%	746,184	39,380	4.81%	68,888	8.41%	3,812	0.47%
#48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	252,617	223,629	88.52%	223,630	16,178	6.40%	26,126	10.34%	2,861	1.13%
#49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	60,370	44,943	74.45%	44,951	2,863	4.74%	15,160	25.11%	94	0.16%
#50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	56,572	42,997	76.00%	43,002	2,724	4.82%	13,227	23.38%	185	0.33%
#51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	90,849	82,269	90.56%	82,269	0	0.00%	8,249	9.08%	266	0.29%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Clinical Condition and Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	77,275	58,345	75.50%	71,350	0	0.00%	5,539	7.17%	344	0.45%
#53 Asthma: Pharmacologic Therapy	6,960	1,475	21.19%	1,700	5,073	72.89%	4,697	67.49%	13	0.19%
#54 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	1,183,208	861,516	72.81%	861,532	14,229	1.20%	318,197	26.89%	2,394	0.20%
#55 12-Lead Electrocardiogram (ECG) Performed for Syncope	1,165,021	256,221	21.99%	256,222	208,286	17.88%	904,283	77.62%	690	0.06%
#56 Community-Acquired Pneumonia (CAP): Vital Signs	414,424	306,152	73.87%	306,170	6	0.00%	30,706	7.41%	1,765	0.43%
#57 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	438,609	336,408	76.70%	336,408	5	0.00%	20,074	4.58%	1,835	0.42%
#58 Community-Acquired Pneumonia (CAP): Assessment of Mental Status	398,813	307,296	77.05%	307,317	5	0.00%	14,625	3.67%	1,649	0.41%
#59 Community-Acquired Pneumonia (CAP): Empiric Antibiotic	284,584	218,072	76.63%	218,072	4	0.00%	10,394	3.65%	1,310	0.46%
#64 Asthma: Asthma Assessment	4,621	948	20.52%	948	3,591	77.71%	3,166	68.51%	1	0.02%
#65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	875	3	0.34%	3	872	99.66%	826	94.40%	0	0.00%
#66 Appropriate Testing for Children with Pharyngitis	917	2	0.22%	2	914	99.67%	869	94.77%	0	0.00%
#67 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	12,315	11,544	93.74%	11,544	0	0.00%	747	6.07%	22	0.18%
#68 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	7,900	7,139	90.37%	7,470	0	0.00%	410	5.19%	17	0.22%
#69 Multiple Myeloma: Treatment with Bisphosphonates	10,219	9,738	95.29%	9,738	0	0.00%	463	4.53%	7	0.07%
#70 Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	12,759	12,132	95.09%	12,132	0	0.00%	605	4.74%	22	0.17%
#71 Breast Cancer: Hormonal Therapy for Stage IC-III C Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	64,099	57,471	89.66%	61,822	237	0.37%	2,134	3.33%	124	0.19%
#72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	17,117	15,200	88.80%	16,145	0	0.00%	944	5.51%	23	0.13%
#76 Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	217,812	192,861	88.54%	192,866	0	0.00%	23,353	10.72%	1,593	0.73%
#79 End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	8,998	4,289	47.67%	4,289	1	0.01%	4,507	50.09%	5	0.06%
#84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	2,820	2,476	87.80%	2,573	0	0.00%	240	8.51%	7	0.25%
#85 Hepatitis C: HCV Genotype Testing Prior to Treatment	2,612	2,292	87.75%	2,454	0	0.00%	152	5.82%	6	0.23%
#86 Hepatitis C: Antiviral Treatment Prescribed	1,539	1,399	90.90%	1,399	0	0.00%	137	8.90%	3	0.19%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Clinical Condition and Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	1,401	1,201	85.72%	1,243	0	0.00%	157	11.21%	1	0.07%
#89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	2,470	2,106	85.26%	2,110	0	0.00%	356	14.41%	3	0.12%
#90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	413	224	54.24%	263	0	0.00%	139	33.66%	1	0.24%
#91 Acute Otitis Externa (AOE): Topical Therapy	4,715	4,374	92.77%	4,374	0	0.00%	311	6.60%	30	0.64%
#92 Acute Otitis Externa (AOE): Pain Assessment	6,630	5,150	77.68%	5,151	0	0.00%	1,432	21.60%	37	0.56%
#93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	3,627	3,345	92.22%	3,354	0	0.00%	253	6.98%	20	0.55%
#94 Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	333	2	0.60%	2	329	98.80%	294	88.29%	0	0.00%
#99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	46,079	25,479	55.29%	25,488	0	0.00%	20,194	43.82%	173	0.38%
#100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	44,108	15,215	34.49%	15,223	0	0.00%	28,081	63.66%	137	0.31%
#102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	6,547	3,420	52.24%	3,577	0	0.00%	2,887	44.10%	72	1.10%
#104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	4,221	3,228	76.47%	3,349	0	0.00%	800	18.95%	72	1.71%
#105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	4,918	3,946	80.24%	4,090	0	0.00%	722	14.68%	77	1.57%
#106 Major Depressive Disorder (MDD): Diagnostic Evaluation	12,013	7,486	62.32%	7,486	0	0.00%	4,379	36.45%	83	0.69%
#107 Major Depressive Disorder (MDD): Suicide Risk Assessment	34,558	22,046	63.79%	22,046	0	0.00%	12,205	35.32%	172	0.50%
#108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	29,493	28,322	96.03%	28,335	0	0.00%	1,101	3.73%	52	0.18%
#109 Osteoarthritis (OA): Function and Pain Assessment	82,986	66,367	79.97%	66,369	1	0.00%	15,525	18.71%	816	0.98%
#110 Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	754,060	723,356	95.93%	723,356	10,664	1.41%	27,253	3.61%	3,451	0.46%
#111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	781,808	735,888	94.13%	736,147	23,996	3.07%	40,722	5.21%	4,939	0.63%
#112 Preventive Care and Screening: Screening Mammography	185,651	127,846	68.86%	127,881	48,244	25.99%	51,430	27.70%	6,340	3.42%
#113 Preventive Care and Screening: Colorectal Cancer Screening	484,468	390,630	80.63%	390,810	78,477	16.20%	85,621	17.67%	8,037	1.66%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Clinical Condition and Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	889	225	25.31%	226	578	65.02%	627	70.53%	12	1.35%
#117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	654,748	420,754	64.26%	421,892	216,688	33.09%	223,238	34.10%	977	0.15%
#119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	91,431	73,126	79.98%	73,147	15,537	16.99%	16,028	17.53%	449	0.49%
#121 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	18,608	11,325	60.86%	11,326	0	0.00%	7,159	38.47%	87	0.47%
#122 Chronic Kidney Disease (CKD): Blood Pressure Management	132,401	21,164	15.98%	23,605	1	0.00%	108,272	81.78%	43	0.03%
#123 Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	24,203	14,165	58.53%	15,811	1	0.00%	8,347	34.49%	11	0.05%
#124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	10,750,499	10,217,948	95.05%	10,217,948	0	0.00%	473,941	4.41%	58,608	0.55%
#126 Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	136,266	121,266	88.99%	121,266	0	0.00%	14,375	10.55%	560	0.41%
#127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	102,833	95,518	92.89%	95,518	0	0.00%	6,837	6.65%	424	0.41%
#128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	694,789	661,906	95.27%	661,906	2	0.00%	28,482	4.10%	4,401	0.63%
#130 Documentation of Current Medications in the Medical Record	5,593,073	5,346,740	95.60%	5,346,740	54	0.00%	216,151	3.86%	30,182	0.54%
#131 Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	464,201	353,359	76.12%	353,359	5	0.00%	99,728	21.48%	11,114	2.39%
#134 Screening for Clinical Depression and Follow-Up Plan	19,914	14,769	74.16%	14,769	0	0.00%	4,540	22.80%	605	3.04%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	2,894	847	29.27%	847	0	0.00%	1,971	68.11%	0	0.00%
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	598,075	576,370	96.37%	578,799	621	0.10%	18,350	3.07%	859	0.14%
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	232,020	199,926	86.17%	210,690	0	0.00%	20,882	9.00%	374	0.16%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	104,757	70,621	67.41%	70,646	1	0.00%	33,249	31.74%	666	0.64%
#145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	717,881	673,784	93.86%	673,976	0	0.00%	39,383	5.49%	4,522	0.63%
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	1,614,811	1,564,606	96.89%	1,569,805	0	0.00%	39,986	2.48%	3,327	0.21%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Clinical Condition and Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	140,246	137,248	97.86%	137,257	0	0.00%	2,625	1.87%	363	0.26%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	12,050	8,156	67.68%	8,156	0	0.00%	3,852	31.97%	19	0.16%
#154 Falls: Risk Assessment	366,572	282,553	77.08%	328,118	28,107	7.67%	34,994	9.55%	3,460	0.94%
#155 Falls: Plan of Care	80,093	42,063	52.52%	42,064	0	0.00%	0	0.00%	3,218	4.02%
#156 Oncology: Radiation Dose Limits to Normal Tissues	1,949	1,639	84.09%	1,639	0	0.00%	283	14.52%	19	0.97%
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	653	460	70.44%	460	0	0.00%	191	29.25%	1	0.15%
#158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	3,508	3,428	97.72%	3,428	0	0.00%	70	2.00%	10	0.29%
#163 Diabetes Mellitus: Foot Exam	132,209	87,965	66.53%	87,970	35,455	26.82%	39,942	30.21%	749	0.57%
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	3,608	3,182	88.19%	3,182	2	0.06%	396	10.98%	30	0.83%
#173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	395,724	382,944	96.77%	382,945	1	0.00%	11,209	2.83%	1,570	0.40%
#175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	0	0	0.00%	0	0	0.00%	0	0.00%	0	0.00%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	12,039	10,696	88.84%	11,809	0	0.00%	210	1.74%	13	0.11%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	12,509	12,240	97.85%	12,240	0	0.00%	245	1.96%	20	0.16%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	13,696	12,823	93.63%	12,823	0	0.00%	840	6.13%	20	0.15%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	8,281	8,143	98.33%	8,162	0	0.00%	113	1.36%	6	0.07%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	8,802	8,422	95.68%	8,671	0	0.00%	118	1.34%	13	0.15%
#181 Elder Maltreatment Screen and Follow-Up Plan	2,731	1,185	43.39%	1,185	159	5.82%	1,493	54.67%	53	1.94%
#182 Functional Outcome Assessment in Chiropractic Care	148,655	142,027	95.54%	142,027	5	0.00%	5,688	3.83%	940	0.63%
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	1,603	1,491	93.01%	1,491	0	0.00%	108	6.74%	4	0.25%
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	1,547	1,441	93.15%	1,442	0	0.00%	101	6.53%	4	0.26%
#185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	32,687	28,092	85.94%	28,092	0	0.00%	4,257	13.02%	94	0.29%
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	2,073	1,354	65.32%	1,354	0	0.00%	701	33.82%	0	0.00%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Clinical Condition and Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	2,064	1	0.05%	1	0	0.00%	2,024	98.06%	0	0.00%
#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	869	36	4.14%	38	0	0.00%	824	94.82%	1	0.12%
#190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	2,526	1,960	77.59%	1,980	0	0.00%	533	21.10%	13	0.51%
#193 Perioperative Temperature Management	1,939,187	1,824,622	94.09%	1,872,447	0	0.00%	61,500	3.17%	5,240	0.27%
#194 Oncology: Cancer Stage Documented	71,146	66,237	93.10%	66,277	0	0.00%	4,617	6.49%	220	0.31%
#195 Radiology: Stenosis Measurement in Carotid Imaging Studies	416,672	389,507	93.48%	390,065	0	0.00%	24,896	5.97%	1,711	0.41%
#201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	168,333	155,664	92.47%	165,365	0	0.00%	2,402	1.43%	512	0.30%
#202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	161,842	159,258	98.40%	159,258	0	0.00%	2,193	1.36%	316	0.20%
#203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	108,332	107,116	98.88%	107,116	0	0.00%	909	0.84%	249	0.23%
#204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Anti-thrombotic	171,749	168,954	98.37%	168,954	0	0.00%	2,194	1.28%	507	0.30%
#225 Radiology: Reminder System for Mammograms	753,950	48,984	6.50%	48,985	819	0.11%	693,302	91.96%	11,498	1.53%
#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	2,080,263	2,018,739	97.04%	2,019,740	9	0.00%	52,639	2.53%	7,884	0.38%
#231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting	18,212	217	1.19%	217	17,199	94.44%	17,078	93.77%	2	0.01%
#232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	33,749	155	0.46%	373	29,456	87.28%	31,671	93.84%	1	0.00%
#235 Hypertension (HTN): Plan of Care	85,896	62,190	72.40%	79,433	0	0.00%	5,395	6.28%	945	1.10%
Total	46,751,052	40,067,691	85.70%	40,375,111	1,068,968	2.29%	5,760,942	12.32%	237,509	0.51%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.